Cargando…
A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
Light chain (AL) amyloidosis is a rare disease associated with significant, irreversible organ dysfunction and high case fatality. An observational study was conducted to assess health‐related quality of life (HRQoL) in patients treated for AL amyloidosis between 1994 and 2014 with both high dose me...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697591/ https://www.ncbi.nlm.nih.gov/pubmed/28850697 http://dx.doi.org/10.1111/bjh.14889 |
_version_ | 1783280645684854784 |
---|---|
author | Sanchorawala, Vaishali McCausland, Kristen L. White, Michelle K. Bayliss, Martha S. Guthrie, Spencer D. Lo, Stephen Skinner, Martha |
author_facet | Sanchorawala, Vaishali McCausland, Kristen L. White, Michelle K. Bayliss, Martha S. Guthrie, Spencer D. Lo, Stephen Skinner, Martha |
author_sort | Sanchorawala, Vaishali |
collection | PubMed |
description | Light chain (AL) amyloidosis is a rare disease associated with significant, irreversible organ dysfunction and high case fatality. An observational study was conducted to assess health‐related quality of life (HRQoL) in patients treated for AL amyloidosis between 1994 and 2014 with both high dose melphalan and stem cell transplantation (HDM/SCT) or non‐SCT chemotherapy regimens. The SF‐36v1(®) Health Survey (SF‐36) was administered to assess HRQoL during clinic visits. Analysis of variance was used to compare pre‐ and post‐treatment HRQoL within each treatment group to an age‐ and gender‐adjusted general population (GP) normative sample. Cox proportional hazard models were fit to examine associations between pre‐treatment levels of HRQoL and mortality within 1 and 5 years after initiating specific treatment regimens (HDM/SCT: n = 402; non‐SCT chemotherapy regimens: n = 172). Among patients who received HDM/SCT, there were significant improvements following treatment in vitality, social functioning, role‐emotional and mental health. Worse pre‐treatment SF‐36 physical component scores were associated with a greater risk of mortality in both treatment groups and follow‐up periods (P ≤ 0·005 for both). [Correction added on 20 October 2017, after first online publication: This P value has been corrected]. Using HRQoL assessments in every physician visit or treatment may provide valuable insights for treating rare conditions like AL amyloidosis. |
format | Online Article Text |
id | pubmed-5697591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56975912017-11-28 A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time Sanchorawala, Vaishali McCausland, Kristen L. White, Michelle K. Bayliss, Martha S. Guthrie, Spencer D. Lo, Stephen Skinner, Martha Br J Haematol Haematological Malignancy Light chain (AL) amyloidosis is a rare disease associated with significant, irreversible organ dysfunction and high case fatality. An observational study was conducted to assess health‐related quality of life (HRQoL) in patients treated for AL amyloidosis between 1994 and 2014 with both high dose melphalan and stem cell transplantation (HDM/SCT) or non‐SCT chemotherapy regimens. The SF‐36v1(®) Health Survey (SF‐36) was administered to assess HRQoL during clinic visits. Analysis of variance was used to compare pre‐ and post‐treatment HRQoL within each treatment group to an age‐ and gender‐adjusted general population (GP) normative sample. Cox proportional hazard models were fit to examine associations between pre‐treatment levels of HRQoL and mortality within 1 and 5 years after initiating specific treatment regimens (HDM/SCT: n = 402; non‐SCT chemotherapy regimens: n = 172). Among patients who received HDM/SCT, there were significant improvements following treatment in vitality, social functioning, role‐emotional and mental health. Worse pre‐treatment SF‐36 physical component scores were associated with a greater risk of mortality in both treatment groups and follow‐up periods (P ≤ 0·005 for both). [Correction added on 20 October 2017, after first online publication: This P value has been corrected]. Using HRQoL assessments in every physician visit or treatment may provide valuable insights for treating rare conditions like AL amyloidosis. John Wiley and Sons Inc. 2017-08-29 2017-11 /pmc/articles/PMC5697591/ /pubmed/28850697 http://dx.doi.org/10.1111/bjh.14889 Text en © 2017 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Haematological Malignancy Sanchorawala, Vaishali McCausland, Kristen L. White, Michelle K. Bayliss, Martha S. Guthrie, Spencer D. Lo, Stephen Skinner, Martha A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time |
title | A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time |
title_full | A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time |
title_fullStr | A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time |
title_full_unstemmed | A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time |
title_short | A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time |
title_sort | longitudinal evaluation of health‐related quality of life in patients with al amyloidosis: associations with health outcomes over time |
topic | Haematological Malignancy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697591/ https://www.ncbi.nlm.nih.gov/pubmed/28850697 http://dx.doi.org/10.1111/bjh.14889 |
work_keys_str_mv | AT sanchorawalavaishali alongitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT mccauslandkristenl alongitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT whitemichellek alongitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT baylissmarthas alongitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT guthriespencerd alongitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT lostephen alongitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT skinnermartha alongitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT sanchorawalavaishali longitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT mccauslandkristenl longitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT whitemichellek longitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT baylissmarthas longitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT guthriespencerd longitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT lostephen longitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime AT skinnermartha longitudinalevaluationofhealthrelatedqualityoflifeinpatientswithalamyloidosisassociationswithhealthoutcomesovertime |